CSPIA
ATRA icon

Cary Street Partners Investment Advisory’s Atara Biotherapeutics ATRA Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3
Closed -$98 – 708
2023
Q3 		$98 Hold
3
– – ﹤0.01% 1848
2023
Q2 		$106 Buy
+3
New +$170 ﹤0.01% 1728

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cary Street Partners Investment Advisory's ATRA Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 3 shares — an estimated $98 sold.

Cary Street Partners Investment Advisory first reported a position in ATRA in Q2 2023 and held it in 2 quarters. The position peaked at $106 in Q2 2023. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 3 Atara Biotherapeutics shares in Q4 2023, an estimated $98.
  • Cary Street Partners Investment Advisory first reported a position in Atara Biotherapeutics in Q2 2023 and held it in 2 quarters.
  • Cary Street Partners Investment Advisory's Atara Biotherapeutics position peaked at $106 in Q2 2023.
  • 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.